In brief: BRCA1 and BRCA2
- PMID: 23620175
- DOI: 10.1002/path.4205
In brief: BRCA1 and BRCA2
Abstract
The discovery of the first major breast cancer susceptibility gene, BRCA1, occurred almost 20 years ago. BRCA1, together with BRCA2 remain the most important discoveries in human cancer genetics. Identification of highly penetrant mutations in these two tumour suppressor genes has had broad implications for women at risk and their families, for health professionals caring for these persons and for basic researchers. The BRCA proteins have many critical functions, the most notable of which, from a clinical perspective, is repair of double-strand DNA breaks.
Keywords: DNA repair; PARP; breast cancer; cisplatinum; ovarian cancer; pathology; targeted therapy; triple negative.
Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Similar articles
-
Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.Breast Cancer Res Treat. 2010 Sep;123(2):581-5. doi: 10.1007/s10549-010-0818-y. Epub 2010 Mar 11. Breast Cancer Res Treat. 2010. PMID: 20221693
-
Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.Breast Cancer Res Treat. 2010 Dec;124(3):643-51. doi: 10.1007/s10549-010-0805-3. Epub 2010 Mar 4. Breast Cancer Res Treat. 2010. PMID: 20204502
-
Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.Breast Cancer Res Treat. 2011 Feb;126(1):119-30. doi: 10.1007/s10549-010-1325-x. Epub 2011 Jan 4. Breast Cancer Res Treat. 2011. PMID: 21203900
-
Breast cancer susceptibility testing: past, present and future.Expert Rev Anticancer Ther. 2006 Aug;6(8):1205-14. doi: 10.1586/14737140.6.8.1205. Expert Rev Anticancer Ther. 2006. PMID: 16925486 Review.
-
BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers.Crit Rev Oncol Hematol. 2006 Jan;57(1):1-23. doi: 10.1016/j.critrevonc.2005.05.003. Epub 2005 Dec 6. Crit Rev Oncol Hematol. 2006. PMID: 16337408 Review.
Cited by
-
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.Cell Rep. 2018 Dec 11;25(11):2972-2980.e5. doi: 10.1016/j.celrep.2018.11.054. Cell Rep. 2018. PMID: 30540933 Free PMC article.
-
Proteomic analysis of differential expression of lung proteins in response to highly pathogenic avian influenza virus infection in chickens.Arch Virol. 2022 Jan;167(1):141-152. doi: 10.1007/s00705-021-05287-5. Epub 2021 Nov 16. Arch Virol. 2022. PMID: 34786609
-
Scaling up to study brca2: the zeppelin zebrafish mutant reveals a role for brca2 in embryonic development of kidney mesoderm.Cancer Cell Microenviron. 2018;5(1):e1630. doi: 10.14800/ccm.1630. Epub 2018 Apr 9. Cancer Cell Microenviron. 2018. PMID: 29707605 Free PMC article.
-
Ginsenosides synergize with mitomycin C in combating human non-small cell lung cancer by repressing Rad51-mediated DNA repair.Acta Pharmacol Sin. 2018 Mar;39(3):449-458. doi: 10.1038/aps.2017.53. Epub 2017 Aug 24. Acta Pharmacol Sin. 2018. PMID: 28836581 Free PMC article.
-
A copula-based set-variant association test for bivariate continuous, binary or mixed phenotypes.Int J Biostat. 2022 Oct 24;19(2):369-387. doi: 10.1515/ijb-2022-0010. eCollection 2023 Nov 1. Int J Biostat. 2022. PMID: 36279152 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous